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Background: Correlations between development of hand–foot syndrome (HFS) and efficacy in patients receiving capecitabine
(CAP)-containing therapy are reported in the literature. We explored the relationship between HFS and efficacy in patients
receiving CAP plus bevacizumab (BEV) in the TURANDOT randomised phase III trial.
Methods: Patients with HER2-negative locally recurrent/metastatic breast cancer (LR/mBC) who had received no prior
chemotherapy for LR/mBC were randomised to BEV plus paclitaxel or BEV–CAP until disease progression or unacceptable
toxicity. This analysis included patients randomised to BEV–CAP who receivedX1 CAP dose. Potential associations between HFS
and both overall survival (OS; primary end point) and progression-free survival (PFS; secondary end point) were explored using
Cox proportional hazards analyses with HFS as a time-dependent covariate (to avoid overestimating the effect of HFS on efficacy).
Landmark analyses were also performed.
Results: Among 277 patients treated with BEV–CAP, 154 (56%) developed HFS. In multivariate analyses, risk of progression or
death was reduced by 44% after the occurrence of HFS; risk of death was reduced by 56%. The magnitude of effect on OS
increased with increasing HFS grade. In patients developing HFS within the first 3 months, median PFS from the 3-month landmark
was 10.0 months vs 6.2 months in patients without HFS. Two-year OS rates were 63% and 44%, respectively.
Conclusions: This exploratory analysis indicates that HFS occurrence is a strong predictor of prolonged PFS and OS in patients
receiving BEV–CAP for LR/mBC. Early appearance of HFS may help motivate patients to continue therapy.
*Correspondence: Professor C Zielinski; E-mail: christoph.zielinski@meduniwien.ac.at
Received 15 June 2015; revised 8 October 2015; accepted 11 November 2015; published online 10 December 2015
& 2016 Cancer Research UK. All rights reserved 0007 – 0920/16
FULL PAPER
Keywords: Capecitabine; bevacizumab; metastatic breast cancer; predictive factor; phase III; fluoropyrimidine
British Journal of Cancer (2016) 114, 163–170 | doi: 10.1038/bjc.2015.419
www.bjcancer.com |DOI:10.1038/bjc.2015.419 163
In four randomised phase III trials, the addition of bevacizumab
(BEV) to first-line chemotherapy has been shown to significantly
improve progression-free survival (PFS) and overall response rate
(Miller et al, 2007; Miles et al, 2010, 2015; Robert et al, 2011), but
no effect on overall survival (OS) has been detected. The
randomised phase III TURANDOT trial by the Central European
Cooperative Oncology Group compared first-line bevacizumab
plus paclitaxel (BEV–PAC) vs bevacizumab plus capecitabine
(BEV–CAP) in patients with HER2-negative locally recurrent or
metastatic breast cancer (LR/mBC) (Lang et al, 2013). Results from
the pre-specified interim analysis were inconclusive for the primary
end point (non-inferior OS with BEV–CAP vs BEV–PAC), but
demonstrated significantly superior PFS (secondary end point)
with BEV–PAC vs BEV–CAP (hazard ratio (HR), 1.36 (95%
confidence interval (CI) 1.09–1.68); P¼ 0.0052; median PFS 11.0
and 8.1 months, respectively).
Post hoc exploratory analyses suggested differing treatment
effects on OS according to clinical risk factors (Brodowicz et al,
2014). In the subgroup of patients with low-risk hormone receptor-
positive disease (defined as one or none of the following risk
factors: disease-free interval p24 months; visceral metastases;
prior anthracycline and/or taxane; or X3 metastatic organ sites),
there was a nonsignificant trend in OS favouring BEV–CAP. In the
absence of a predictive biomarker for efficacy of either CAP or
BEV, this risk factor index based on clinical characteristics may
help in selecting patients for initial BEV–CAP therapy, balancing
tolerability, patient preference, and efficacy. Several reports in the
literature suggest that hand–foot syndrome (HFS) – a well-known
side effect of CAP – may also be of interest in predicting the
efficacy of CAP-containing therapy. An exploratory analysis of a
small single-arm Japanese study suggested that HFS occurrence in
CAP-treated patients may be associated with improved efficacy
(Taguchi et al, 2010). Similar observations were reported from two
retrospective studies, each including almost 100 patients receiving
various CAP-containing regimens for metastatic breast cancer
(mBC) (Kurt et al, 2006; Azuma et al, 2012). A relationship
between HFS development and efficacy was also noted in the larger
single-arm prospective MONICA trial evaluating first-line CAP
monotherapy for mBC (Kaufmann et al, 2010). Median time to
disease progression (TTP) was 9.4 months in patients developing
HFS vs 4.7 months in those without (P¼ 0.0542); median OS was
22.9 and 14.2 months, respectively (P¼ 0.0209). HFS was an
independent prognostic factor for TTP and OS in univariate and
multivariate analyses. However, a major limitation of these
analyses, as well as their retrospective nature, is the bias introduced
by the association between treatment duration and likelihood of
developing HFS. HFS is a cumulative toxicity with a reported
median time to onset of almost 8 months in a meta-analysis of
more than 4700 patients receiving CAP-based therapy for various
tumour types (Roche, 2014). Patients whose disease is controlled
with CAP tend to have longer treatment exposure and conse-
quently an increased likelihood of developing HFS, whereas
patients who die or experience progression very early are less
likely to develop HFS. This is illustrated by the previously
mentioned analysis of the TURANDOT trial according to a simple
prognostic factor index (Brodowicz et al, 2014). In patients with
low-risk hormone receptor-positive disease, who appeared to
derive the greatest benefit from BEV–CAP, the incidence of grade
3 HFS was 28% compared with 14% in those with high-risk
hormone receptor-positive disease and 12% in those with triple-
negative breast cancer. Corresponding median durations of CAP
exposure were 8.3, 7.4, and 5.7 months, respectively. Clearly, a
simple comparison of PFS and OS curves between patients with
and without HFS during study treatment is likely to lead to an
overestimation of the effect of HFS on efficacy.
In the X-ACT trial in stage III colon cancer, post hoc exploratory
retrospective analyses of HFS were less confounded by treatment
duration because patients received a fixed 24-week course of
adjuvant CAP therapy and the probability of an event (relapse or
death) before HFS occurred was relatively low, and lower than in
LR/mBC. Interestingly, these analyses also suggested a relationship
between HFS and efficacy. Patients experiencing HFS during CAP
treatment had numerically better disease-free survival and OS than
those without HFS (Twelves et al, 2012).
To explore a potential correlation between HFS and efficacy in
patients receiving first-line BEV–CAP for HER2-negative LR/mBC,
we performed analyses of the patients randomised to BEV–CAP in
the TURANDOT trial, assessing whether the occurrence of HFS
constituted an on-treatment predictive marker for improved
efficacy of BEV–CAP.
PATIENTS AND METHODS
In the open-label randomised phase III non-inferiority TURAN-
DOT trial, patients with HER2-negative LR/mBC who had received
no prior chemotherapy for LR/mBC were randomly assigned to
receive either BEV–PAC (BEV 10mg kg 1 on days 1 and 15 plus
paclitaxel 90mgm 2 on days 1, 8, and 15, repeated every 4 weeks)
or BEV–CAP (BEV 15mg kg 1 on day 1 plus CAP 1000mgm 2
twice daily on days 1–14, repeated every 3 weeks). The primary end
point in the TURANDOT trial was OS; PFS was a secondary end
point. Sample size calculations and statistical methods for the trial
have been reported previously (Lang et al, 2013). In the present
analyses, only patients randomised to BEV–CAP who received at
least one dose of CAP were included.
Adverse events were graded according to Common Terminol-
ogy Criteria for Adverse Events (version 3.0) at every cycle
throughout the study and for 28 days after treatment discontinua-
tion. If patients experienced grade 2 or 3 HFS, CAP treatment was
interrupted until HFS improved to grade 0 or 1. Subsequent doses
of CAP were decreased to 75% of the starting dose at the first
occurrence of grade 2 or 3 HFS, and to 50% of the starting dose at
the second occurrence. If patients experienced a third HFS episode,
CAP was discontinued permanently. Vitamin B6 was permitted for
symptomatic or secondary prophylactic treatment of HFS.
All patients provided written informed consent before study
entry. The institutional review board of each participating
institution approved the study protocol.
The association between HFS and OS or PFS was analysed using
Cox proportional hazards adjusted for various baseline character-
istics. Kaplan–Meier methods were used to visualise PFS and OS
curves and estimate survival rates at various time points for
patients with and without HFS. To avoid overestimating the effect
of HFS on efficacy, as mentioned earlier, the primary analysis of
the association between HFS and PFS or OS used Cox proportional
hazard methods with HFS as a time-dependent covariate. In the
first analysis, the occurrence of HFS irrespective of grade was
considered as a time-dependent variable (level 1 for all days after
the first HFS occurrence, level 0 for all days preceding the first
occurrence and all days in patients without HFS). In the second
analysis, HFS grade (1, 2, or 3 vs no HFS) was considered as a time-
dependent variable. The highest grade was assumed for all days
after the first occurrence of HFS, even if HFS subsequently
improved or resolved completely. Stepwise selection procedures
with significance levels of Po0.1 for entering and Po0.05 for
staying in the model were used after preselection of covariates in a
preceding univariate step (univariate Po0.25).
Additional Cox proportional hazards landmark analyses were used
to investigate the impact of early HFS occurrence (during the first 3
months of treatment) on PFS and OS. The landmark was set at
treatment day 91; patients with a PFS or OS event before the landmark
were excluded from the corresponding analyses. Kaplan–Meier
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methods were used to visualise PFS and OS curves and estimate
survival rates across time points. The advantage of the landmark
analysis (similar to the Cox model with HFS as a time-dependent
covariate) is that effects of HFS on PFS or OS are not overestimated;
however, this approach ignores the effect of HFS on events before the
landmark, unlike the time-dependent covariate in the Cox model.
RESULTS
The analysis population included 277 patients treated with
BEV–CAP (Figure 1). HFS was the most common adverse event
(56% of patients overall), followed by hypertension (29%) and
fatigue (27%). Among the 154 patients experiencing HFS, this
event occurred at grade 1 in 54 patients (19%), grade 2 in 55
patients (20%), grade 3 in 44 patients (16%), and at unknown
grade in 1 patient. The remaining 123 patients (44%) did not
develop HFS during study treatment. Baseline characteristics were
quite similar between patients with vs without HFS (Table 1). The
main differences were the higher proportions of patients in the
non-HFS subgroup with lung metastases, X3 metastatic organ
sites, and hormone receptor-negative disease, and the lower
proportion with prior endocrine therapy for LR/mBC (consistent
with the difference in hormone receptor status).
Table 2 summarises treatment exposure. The most common
reason for discontinuing BEV and/or CAP in both subgroups was
disease progression. In the HFS subgroup, disease progression led
to BEV discontinuation in 62% of patients and CAP discontinua-
tion in 60%. Corresponding percentages in patients without HFS
were 65% and 67%, respectively. Adverse events leading to
discontinuation of BEV were observed in 11% of patients who
developed HFS and 20% of those who did not experience HFS; for
CAP discontinuation, the proportion was 19% in both subgroups.
The median duration of follow-up at the data cutoff for this
analysis was 20.5 months (95% CI 18.0–21.2 months) in patients
developing HFS vs 18.0 months (95% CI 16.1–18.7 months) in
those without HFS. At this time PFS events had occurred in 214
patients (77%) and 97 (35%) had died. The most common cause of
Assessed for eligibility (n = 604)
Randomised (n = 564)
Bevacizumab + capecitabine (n = 279)Bevacizumab + paclitaxel (n = 285)Intent-to-treatpopulation
Safety
population
Excluded (n = 40)
• Inclusion criteria not met (n = 35)
• Declined to participate (n = 4)
• Other reason (n = 1)
Did not receive treatment
• Consent withdrawn (n = 1)
• Randomisation failure (n = 1)
Received treatment (n = 277)
• Developed HFS (n = 154)
• Did not develop HFS (n = 123)
Received treatment (n = 284)
Did not receive treatment
• Consent withdrawn (n = 1)
Figure 1. Patient flow. HFS=hand-foot syndrome.
Table 1. Baseline characteristics of patients randomised to
bevacizumab plus capecitabine according to development or
not of hand–foot syndrome
No. of patients (%)
Characteristics HFS (n¼154) No HFS (n¼123)
Median age, years (range) 59 (27–86) 58 (28–82)
Menopausal status
Pre-menopausal 30 (19.5) 20 (16.3)
Post-menopausal 121 (78.6) 102 (82.9)
Male 3 (1.9) 1 (0.8)
ECOG performance status
0 105 (68.2) 74 (60.2)
1 47 (30.5) 44 (35.8)
2 2 (1.3) 5 (4.1)
Hormone receptor status
ER and/or PgR positive 124 (80.5) 86 (69.9)
ER and PgR negative 30 (19.5) 37 (30.1)
Metastatic at first diagnosis 32 (20.8) 26 (21.1)
Disease-free interval
p12 months 4 (2.6) 6 (4.9)
412–p24 months 19 (12.3) 14 (11.4)
424 months 96 (62.3) 75 (61.0)
No disease-free intervala 35 (22.7) 28 (22.8)
Metastatic organ sites
Visceral 113 (73.4) 89 (72.4)
Liver 71 (46.1) 54 (43.9)
Lung 61 (39.6) 61 (49.6)
Soft tissue and/or bone only 15 (9.7) 8 (6.5)
X3 metastatic organ sites 63 (40.9) 60 (48.8)
Prior endocrine therapy 105 (68.2) 65 (52.8)
For LR/mBC 38 (24.7) 19 (15.4)
Prior (neo)adjuvant
chemotherapy
95 (61.7) 80 (65.0)
Abbreviations: ECOG¼Eastern Cooperative Oncology Group; ER¼oestrogen receptor;
HFS¼ hand–foot syndrome; LR/mBC¼ locally recurrent/metastatic breast cancer;
PgR¼progesterone receptor.
aPatient did not receive or did not respond to therapy for primary breast cancer.
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death in both subgroups was disease progression (32 of 37 patients
(86%) with HFS vs 49 of 60 patients (82%) without HFS). Disease-
related complications resulted in death in three patients in the HFS
subgroup (all 428 days after discontinuing study treatment) and
six patients in the non-HFS subgroup (four patients within 28 days
of stopping study treatment and two patients 428 days after
stopping study treatment). Figure 2 shows PFS and OS. Best overall
response of complete or partial response was achieved in 38% of
patients with HFS vs 14% of those without.
In univariate Cox proportional hazards analyses, HFS was
strongly associated with improved PFS and OS in both the analysis
irrespective of HFS grade and that taking into account HFS severity
(Table 3). Other parameters associated with improved PFS and OS
in univariate Cox proportional hazards analyses were Eastern
Cooperative Oncology Group (ECOG) performance status 0,
hormone receptor-positive disease, absence of lymph node
metastases, absence of lung metastases (OS only), and sum of
tumour diameters p5 cm (OS only). In a subsequent stepwise
selection process with a significance level of Po0.10 to enter the
model and Po0.05 to stay, all parameters with Po0.25 in the
univariate analyses were considered. In the final models,
occurrence of HFS and ECOG performance status 0 (and for OS
only: hormone receptor-positive disease) remained significantly
associated with improved PFS and OS. The same prognostic factors
entered the final models with HFS grading.
Among patients developing HFS, the risk for progression or
death was reduced by more than 40% (HR 0.56 in multivariate
analysis; Table 3); the risk reduction exceeded 55% for OS
(HR 0.44 in multivariate analysis). Further analyses according to
HFS severity indicated that the degree of risk reduction for OS
increased with increasing HFS grade (Table 3). For PFS, a slightly
stronger risk reduction was observed with grade 2 than grade 1
HFS, but the risk reduction was not greater for grade 3 vs grade 2.
In the landmark analyses, median PFS was 10.0 months after the
3-month landmark (95% CI 6.2–13.4 months) in the 92 patients
developing HFS within 3 months of starting study treatment vs 6.2
months (95% CI 5.0–8.3 months) in the 123 patients without HFS
by this time (two-sided log-rank P¼ 0.0026; Figure 3A). The OS
rates 2 years after the landmark were 63% (95% CI 50–74%) in the
105 patients developing HFS within 3 months of starting treatment
vs 44% (95% CI 31–56%) in the remaining 159 patients (two-sided
log-rank P¼ 0.0842; Figure 3B).
Analysis of post-study therapy, which potentially influences
OS, showed slight differences according to the presence or absence
of HFS. Specifically, more patients in the non-HFS than in the HFS
subgroup received second-line chemotherapy (52 and 42%,
respectively) and/or taxane-based therapy (41 and 32%, respectively)
after discontinuing BEV–CAP (Table 4).
DISCUSSION
These exploratory subgroup analyses of the TURANDOT trial
suggest that HFS is a strong predictor for prolonged PFS and OS
in patients receiving first-line BEV–CAP for HER2-negative
LR/mBC. The risk of progression or death was approximately
halved in patients developing HFS, and landmark analyses
support the observed relationship between HFS and efficacy of
BEV–CAP. The results of our post hoc analysis are consistent with
other reports in the literature and with information in the CAP
prescribing information (Roche, 2014). A meta-analysis of 14
clinical trials including more than 4700 patients treated with CAP
(alone or combined with different chemotherapy regimens) in
multiple indications (colon, colorectal, gastric, and breast
cancers) showed that patients receiving CAP who developed
HFS had longer OS than those without HFS (HR 0.61 (95% CI
0.56–0.66); median OS 36.1 and 22.7 months, respectively)
(Roche, 2014).
Comparison of the baseline characteristics suggests an imbal-
ance in the two subgroups, with a potentially less favourable
prognosis in patients who did not experience HFS in terms of
number of metastatic organ sites, lung involvement, hormone
receptor status, and prior endocrine therapy for advanced disease.
However, the HFS effect estimated in the univariate Cox
proportional model remained almost unchanged when adjusted
for baseline characteristics that were significantly prognostic for
PFS and OS.
The early occurrence of HFS may help physicians and patients
to make a qualified decision about continuing CAP therapy.
However, a practical limitation of the present analyses is that these
data do not help in identifying which patients should start
treatment with BEV–CAP rather than, for example, BEV–PAC,
which was associated with superior PFS in the TURANDOT trial.
Thymidine phosphorylase (TP), which has a critical role in the
three-step enzymatic conversion of CAP to 5-fluorouracil at the
tumour site, has attracted interest as a potential predictive marker
for CAP efficacy. Several reports in the literature suggest that
increased tumour TP concentrations may correlate with improved
efficacy of CAP (Puglisi et al, 2008; Andreetta et al, 2009; Zhao
et al, 2012; Bonotto et al, 2013). Interestingly, tumour samples
from a small study in patients receiving CAP plus docetaxel for
Table 2. Treatment exposure in patients randomised to
bevacizumab plus capecitabine according to development or
not of HFS
Treatment
exposure HFS (n¼154) No HFS (n¼123)
Still receiving study therapy at the time of data cut-off, n (%)
Bevacizumab 24 (15.6) 3 (2.4)
Capecitabine 23 (14.9) 3 (2.4)
Mean cumulative dose (s.d.)
Bevacizumab, mg kg 1 236.9 (141.6) 116.4 (100.8)
Capecitabine, mgm2 345 878 (194 926) 198 233 (166 403)
Median cumulative dose (range)
Bevacizumab, mg kg 1 195.1 (15.0–691.4) 90.0 (14.9–573.4)
Capecitabine, mgm2 305 202 (53 029–937 824) 161 204 (4472–912818)
Median treatment duration, months (range)
Bevacizumab 8.9 (o0.1–31.3) 3.5 (o0.1–29.2)
Capecitabine 9.2 (1.1–31.7) 4.5 (0.1–26.0)
Mean relative dose intensity, %
Bevacizumab 99 100
Capecitabine 87 91
Patients with an AE
leading to
bevacizumab and/or
capecitabine
discontinuation, n (%)a
36 (23.4) 29 (23.6)
Bevacizumab and
capecitabine
8 (5.2) 19 (15.4)
Bevacizumab 17 (11.0) 25 (20.3)
Capecitabine 30 (19.5) 23 (18.7)
Patients with an AE
leading to capecitabine
modification, n (%)a
106 (68.8) 41 (33.3)
Interruption 25 (16.2) 7 (5.7)
Dose reduction 52 (33.8) 10 (8.1)
Delay 64 (41.6) 31 (25.2)
Patients with HFS leading to capecitabine adaptation, n (%)a
Discontinuation 16 (10.4) 0
Dose modification 71 (46.1) 0
Abbreviations: AE¼ adverse event; HFS¼ hand–foot syndrome.
aMultiple answers possible.
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non-small-cell lung cancer suggested that high tumour cell TP
concentrations are associated with the development of HFS
(Han et al, 2005). In patients receiving BEV–CAP combination
therapy, TP may be of particular relevance because tumour
cells overexpressing TP grow faster and form more angiogenic
tumours (Jones et al, 2002). Furthermore, TP is commonly
associated with the expression of other pro-angiogenic molecules,
such as vascular endothelial growth factor – the target of BEV
(Toi et al, 1994; Bonotto et al, 2013). Indeed, HFS has been linked
to the efficacy of another anti-angiogenic agent, sorafenib, in
exploratory analyses in patients with hepatocellular and renal cell
cancers (Cho et al, 2013; Nakano et al, 2013; Yada et al, 2014).
Unfortunately there are no tumour tissue samples from
TURANDOT, therefore we cannot explore whether the presence
of HFS is a clinical marker of increased tumour TP concentration.
However, this hypothesis is biologically plausible and merits
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Figure 2. Efficacy according to the development of HFS in patients receiving bevacizumab plus capecitabine treatment. (A) PFS; (B) OS.
CI=confidence interval; HFS=hand-foot syndrome; OS=overall survival; PFS= progression-free survival.
Table 3. Cox proportional hazards models for PFS and OS with HFS as time-dependent covariate
Univariate Multivariatea
End point Time-dependent variable Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value
PFS HFS (yes vs no) 0.577 (0.431–0.772) 0.0002 0.558 (0.409–0.760) 0.0002
Grade 1 HFS 0.639 (0.440–0.927) 0.0184 0.536 (0.350–0.821) 0.0042
Grade 2 HFS 0.481 (0.321–0.720) 0.0004 0.487 (0.320–0.741) 0.0008
Grade 3 HFS 0.641 (0.411–0.999) 0.0495 0.740 (0.466–1.178) 0.2043
OS HFS (yes vs no) 0.417 (0.273–0.637) o0.0001 0.436 (0.285–0.666) 0.0001
Grade 1 HFS 0.568 (0.334–0.968) 0.0375 0.548 (0.322–0.934) 0.0270
Grade 2 HFS 0.417 (0.227–0.765) 0.0048 0.448 (0.243–0.824) 0.0098
Grade 3 HFS 0.220 (0.093–0.520) 0.0006 0.247 (0.104–0.586) 0.0015
Abbreviations: CI¼ confidence interval; HFS¼hand–foot syndrome; OS¼overall survival; PFS¼progression-free survival. Grade 1 HFS was defined as minimal skin changes or dermatitis (e.g.,
erythema) without pain; grade 2 was defined as skin changes (e.g., peeling, blisters, bleeding, oedema) or pain, not interfering with function; and grade 3 was defined as ulcerative dermatitis or
skin changes with pain interfering with function.
aSignificant baseline factors in multivariate models: Eastern Cooperative Oncology Group performance status (0 vs 1/2) in all models; oestrogen receptor/progesterone receptor status (any
positive vs other) in both OS models.
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further investigation, as a pretreatment predictor of efficacy is
perhaps more clinically valuable than an on-treatment predictor of
efficacy. Our study did not include pharmacokinetic evaluation,
which would have enabled investigation of potential differences
between patients with vs without HFS.
In contrast to previous analyses reporting a potential
predictive value of HFS with single-agent CAP for LR/mBC,
patients in TURANDOT received BEV–CAP combination
therapy. If CAP was discontinued because of HFS, patients could
continue to receive BEV as a single agent. However, the approach
taken by clinicians after discontinuing the administration of CAP
may represent another potential imbalance: some may have
considered that as patients could continue to receive BEV, they
remained on active treatment, whereas others may have been
reluctant to continue BEV alone based on the modest single-agent
activity of BEV in LR/mBC, and may therefore have withdrawn
patients from the study or switched them to another chemo-
therapy. Recently, results from the randomised phase III IMELDA
trial provided new information on BEV–CAP maintenance therapy.
In IMELDA, patients with a response or stable disease following
initial BEV–taxane induction therapy were then randomised to
maintenance therapy with BEV alone or BEV–CAP (Gligorov et al,
2014). BEV–CAP maintenance therapy was associated with
statistically significant and clinically relevant improvements in the
primary end point (PFS) and also OS (HR 0.43; P¼ 0.0003; median
OS 39.0 months with BEV–CAP vs 23.7 months with single-agent
maintenance BEV). These findings strongly support switching to
BEV–CAP after initial therapy; however, they do not directly inform
on continuation of BEV–CAP in patients responding to initial
treatment with this combination.
Reports in the literature have also suggested a potential
correlation between hypertension and clinical outcome with anti-
angiogenic therapy in breast cancer and other tumour types
(Schneider et al, 2008; O¨sterlund et al, 2011; Evans, 2012).
However, in a meta-analysis of individual patient data from
almost 6500 patients treated in seven phase III trials of BEV-
containing therapy, including two trials in LR/mBC, early
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Figure 3. Landmark-analysis patients experiencing HFS within the first 3 months of bevacizumab plus capecitabine treatment compared with
those who had not experienced HFS at this landmark. (A) PFS (n¼ 215); (B) OS (n¼ 264). CI=confidence interval; HFS=hand-foot syndrome;
OS=overall survival; PFS=progression-free survival.
Table 4. Post-study therapy in patients randomised to
bevacizumab plus capecitabine according to development or
not of HFS
Treatment, n (%) HFS (n¼154) No HFS (n¼123)
Any therapy 94 (61.0) 81 (65.9)
Hormonal 40 (26.0) 23 (18.7)
Chemotherapy 77 (50.0) 67 (54.5)
Second line 65 (42.2) 64 (52.0)
Third line 35 (22.7) 26 (21.1)
Fourth line 15 (9.7) 7 (5.7)
Further line 12 (7.8) 3 (2.4)
Taxane 49 (31.8) 50 (40.7)
Bevacizumab 9 (5.8) 5 (4.1)
Abbreviation: HFS¼ hand–foot syndrome.
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treatment-related hypertension was neither prognostic nor
predictive for PFS and OS (Hurwitz et al, 2013). On the basis
of these findings, as well as the relatively small number of patients
developing hypertension, we did not perform post hoc analyses of
hypertension in the TURANDOT trial to explore a potential
correlation further.
The greater use of post-study taxane therapy in the non-HFS
subgroup than in the HFS subgroup is interesting, and may suggest
that investigators chose more intensive second-line chemotherapy
for these patients with shorter PFS and OS. Similarly, the higher
proportion of patients in the non-HFS subgroup who received
second-line chemotherapy after discontinuing BEV–CAP
may suggest more intensive treatment, balancing against a
slightly higher proportion of patients receiving endocrine therapy
in the HFS subgroup. These observations are consistent with
clinical practice: if patients have prolonged disease control on
BEV–CAP, physicians may switch to endocrine maintenance
therapy, despite the lack of clinical evidence to support such a
strategy. In contrast, for patients with rapid progression on
BEV–CAP, physicians may select more intensive chemotherapy,
such as a taxane-based regimen, to gain rapid disease control.
This hypothesis is also consistent with the more aggressive
baseline disease characteristics in the non-HFS subgroup.
Alternatively, the greater prevalence of hormone receptor-negative
disease among the non-HFS subgroup may explain the more
frequent use of chemotherapy in these patients. The higher
proportion of patients in the non-HFS group who had experienced
a PFS event at the time of data cutoff may also contribute to the
imbalance in second-line chemotherapy administration, as more
patients in the non-HFS group had the opportunity to receive
further lines of therapy. Finally, the greater attrition in later
chemotherapy lines in the non-HFS subgroup is consistent with
the shorter OS in these patients.
Practically, findings from these subgroup analyses may have
important implications when treating patients with BEV–CAP.
The development of HFS may help motivate patients to continue
their oral therapy, while applying appropriate treatment interrup-
tions and dose modifications to achieve an optimal tolerability/
efficacy balance. Early occurrence of HFS and its severity might
help to guide treatment modifications and increase compliance
with oral chemotherapy. Detection of biomarkers for HFS could
strengthen this approach. The search for more individualised
treatment and personalised health-care remains a high priority,
while analyses such as our findings may help in monitoring and
managing patients receiving BEV–CAP therapy for HER2-negative
LR/mBC.
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